BioCardia, Inc. (BCDA) News
Filter BCDA News Items
BCDA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BCDA News Highlights
- For BCDA, its 30 day story count is now at 2.
- Over the past 1 day, the trend for BCDA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about BCDA are DEC and III.
Latest BCDA News From Around the Web
Below are the latest news stories about BIOCARDIA INC that investors may wish to consider to help them evaluate BCDA as an investment opportunity.
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection FractionSUNNYVALE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announced that the first patient was enrolled and treated in its CardiALLO™ Allogeneic Mesenchymal Cell Therapy Phase I/II trial for the treatment of patients with New York Heart Association Class II and III ischemic heart failure of reduced ejection fraction (HFrEF). These “off the shelf” mese |
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation MinutesSUNNYVALE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Japan Pharmaceutical and Medical Device Agency (PMDA) minutes support the Company’s understanding that CardiAMP autologous cell therapy may be approved for the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) based on follow-up data from th |
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product ApprovalSUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure of reduced ejection fraction (HFrEF). Japan’s PMDA asked for further d |
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesSUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share of common stock in a registered direct offering pr |
BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure StudyThe FDA approves BioCardia's (BCDA) phase III study on its CardiAMP cell therapy to treat patients with ischemic heart failure. |
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart FailureSUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure. BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart F |
BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call TranscriptBioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript November 8, 2023 BioCardia, Inc. reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Ladies and gentlemen, thank you for standing by and welcome to the BioCardia 2023 Third Quarter Conference Call. At this time, all participants are in a listen-only mode. […] |
Q3 2023 BioCardia Inc Earnings CallQ3 2023 BioCardia Inc Earnings Call |
BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business UpdatesInsights into BioCardia's Clinical Developments and Financial Health |
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue EstimatesBioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |